Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€185.00

€185.00

-0.080%
-0.14
-0.080%
€182.50
 
12.09.23 / Tradegate WKN: A1XA8R / Symbol: NONOF / Name: Novo Nordisk / Stock / Pharmaceuticals / Large Cap / We currently do not receive price updates for this security
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Description Novo Nordisk

Novo Nordisk A/S is a global pharmaceutical company that specializes in diabetes care. It was founded in Copenhagen, Denmark in 1923, and is currently listed on the Copenhagen Stock Exchange and on the U.S. OTC market under the symbol NONOF.

The company produces a wide range of products that are used in the treatment of diabetes, including insulin, GLP-1 agonists, and other diabetes-related medications. Novo Nordisk is the world's largest producer of insulin and has a significant market share in the diabetes care segment.

In addition to diabetes care, the company also operates in the areas of hemophilia care, growth hormone therapy, and hormone replacement therapy. Novo Nordisk conducts research and development to advance its products and improve the lives of people with diabetes and other chronic conditions.

The company has operations in over 80 countries, with sales in more than 170 countries. As of 2021, Novo Nordisk has a market capitalization of around $200 billion and is considered one of the largest and most successful pharmaceutical companies in the world.

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Novo Nordisk A/S is only available for our menbers.
Not a member yet? Sign up for free!

Competitors of Novo Nordisk

Novo Nordisk is a multinational pharmaceutical company that develops and produces medications for chronic diseases such as diabetes, obesity, and hemophilia. The company has several competitors in the pharmaceutical sector including:

1. Sanofi (SNY): Sanofi is a multinational pharmaceutical company, headquartered in France, that develops, manufactures, and distributes pharmaceutical products.

2. Eli Lilly and Co (LLY): Eli Lilly is a global pharmaceutical company based in the United States that develops and manufactures drugs for various diseases such as diabetes, cancer, and Alzheimer's disease.

3. GlaxoSmithKline (GSK): GlaxoSmithKline, headquartered in the UK, is a multinational pharmaceutical company that focuses on the development, manufacturing, and marketing of prescription medicines and vaccines.

4. AstraZeneca (AZN): AstraZeneca is a British-Swedish multinational pharmaceutical company that specializes in the research, development, and manufacturing of medicines for various diseases, including diabetes, cancer, respiratory, and cardiovascular diseases.

5. Merck Co. (MRK): Merck Co. is a global pharmaceutical company based in the United States that develops and produces medications for various diseases, including diabetes, cancer, and cardiovascular diseases.

Overall, Novo Nordisk competes with many major pharmaceutical companies in the development and production of medications for chronic diseases. Each company brings a unique set of drugs to the market, and competition in this sector is intense.

Suppliers of Novo Nordisk

Novo Nordisk is a Danish pharmaceutical company that is listed on several stock exchanges, including the OTC market in the US under the symbol NONOF. The company operates globally and produces a wide range of products related to diabetes care, haemophilia, growth hormone therapy, and obesity care.

As a pharmaceutical company, Novo Nordisk relies on a variety of suppliers for their operations. These suppliers provide raw materials, equipment, and services, which are essential for the production of the company's products. Some of the most important suppliers for Novo Nordisk are:

1. Chemical suppliers: Novo Nordisk uses a variety of chemicals in its manufacturing process, such as active pharmaceutical ingredients (APIs) and excipients. The company's top chemical suppliers include Lonza, DSM, and BASF.

2. Packaging suppliers: Novo Nordisk needs to package its products carefully to maintain their quality and safety. The company's main packaging suppliers include Gerresheimer, Berry Global, and Owens-Illinois.

3. Logistics providers: Novo Nordisk relies on logistics providers to transport its products across the globe. The company works with logistics companies such as DHL, FedEx, and UPS to ensure timely and safe delivery of its products.

4. Equipment suppliers: Novo Nordisk needs specialized equipment for its production lines. The company's main equipment suppliers include GE Healthcare, Sartorius, and Thermo Fisher Scientific.

Overall, Novo Nordisk relies on a network of suppliers to maintain its operations and deliver its products to customers worldwide. The company's suppliers play a crucial role in ensuring the quality, safety, and timeliness of its operations.

Financial data and news for Novo Nordisk

sharewise wants to provide you with the best news and tools for Novo Nordisk, so we directly link to the best financial data sources.